Vaccine Update
Updates about SynCon(R) DNA vaccine, melanoma vaccine and Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.
Potential Chagas Vaccine Candidate Shows Efficacy
Researchers at the Sealy Center forVaccine Development at the University of Texas Medical Branch (UTMB) at Galveston have developed a safe vaccine candidate for Chagas disease that is simple to produce and shows a greater than 90 percent protection rate against chronic infection in mice.
Study Shows Protective Properties of Flu Vaccines
Collaborating scientists from Nationwide Children’s Hospital, Baylor Institute for Immunology Research and Mount Sinai School of Medicine have identified an important mechanism for stimulating protective immune responses following seasonal influenza vaccinations.
Influenza Vaccination Associated with Reduced Risk of Major Adverse Cardiovascular Events: Meta-Analysis
A recent Canadian study showed that the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events.
Universal Flu Vaccine Effective in Animals
A recent study showed that a universal flu vaccine induced levels of anti-flu antibodies 34 times higher in mice and 10 times higher in ferrets compared with a traditional vaccine.
Menactra Vaccine May Be Safe During Pregnancy
A study conducted by researchers at the Centers for Disease Control and Prevention found that pregnant women can safely receive the meningococcal vaccine Menactra.
Potential Vaccine Could Be Effective in Newborns After Birth
Researchers at Boston Children’s Hospital have identified a potent compound that activates immune responses in newborns’ white blood cells substantially better than anything previously tested, and that could make vaccines effective right after birth.
Fluzone High-Dose More Effective Than Standard Dose in Older Adults
Results from a large clinical trial of Sanofi Pasteur’s Fluzone High-Dose showed that the influenza vaccine was 24.2 percent more effective against lab-confirmed flu than the traditional vaccine dose in adults 65 and older.
Novavax Inc. Vaccine Update
Novavax Inc. announced positive preclinical data for its virus-like particle (VLP) vaccine candidate against A(H7N9) influenza.
Quadrivalent VLP Vaccine Achieves Phase II Trial Endpoints
Novovax Inc.’s quadrivalent seasonal influenza virus-like particle (VLP) vaccine demonstrated the company’s PhaseII clinical trial’s primary endpoint of safety and immunogenicity of three ascending dose levels.